At the J.P. Morgan Healthcare Conference, CFO Aradhana Sarin reported that AstraZeneca delivered very strong commercial performance in the first nine months of 2025, with total revenue up 11% and core EPS up 15% versus the same period in 2024. Oncology led growth with a 16% increase, biopharmaceuticals rose 8% and rare disease climbed 6%. Newer medicines more than offset the impact of loss of exclusivity for brands such as Brilinta, Pulmicort and Soliris. Regionally, the U.S. market grew 11%, while emerging markets outside China achieved 21% growth. Management reiterated its four-year guidance calling for high single-digit revenue increases and low double-digit core EPS growth at constant exchange rates. Sarin cautioned that fourth-quarter comparisons would be affected by over $800 million in collaboration milestones recorded last year, and highlighted headwinds from volume-based procurement and year-end hospital order dynamics in China, as well as the timing of certain tender processes in emerging markets. AstraZeneca will report full-year results on February 10.

Sarin described 2025 as a catalyst-rich year, with 16 positive Phase 3 readouts representing peak revenue opportunities exceeding $10 billion. Late-year FDA approvals included Imfinzi in perioperative gastric cancer and Enhertu in first-line HER2-positive breast cancer, and the agency accepted baxdrostat for priority review in hypertension. AstraZeneca plans to launch several new medicines in 2026, notably baxdrostat, camizestrant and garadacimab, all currently under regulatory review. These assets build on late-stage successes and are expected to drive sustained growth as mature brands face patent cliffs.

AstraZeneca emphasized a governance framework that ranks all R&D projects collectively to support targeted, science-driven risk-taking rather than fixed budget allocations by therapy area. The company expects full-year 2026 R&D costs toward the upper end of the low-20% range of total revenue to support 104 ongoing Phase 3 studies. Patient enrollment is projected to step up significantly in cardiovascular, renal and metabolism outcome trials. On artificial intelligence, the firm highlighted IDA, an agentic system that could cut time-to-commercial scale-up in synthetic manufacturing by up to 50%, and QCS for computational pathology to identify patients most likely to respond to antibody-drug conjugates. The recent acquisition of Modela AI is set to advance AstraZeneca’s pathology foundation models.

Management reiterated confidence in its $80 billion revenue ambition for 2030, a risk-adjusted target first introduced in May 2024. Consensus estimates have risen from $67 billion at the time of target introduction to roughly $80 billion today. In oncology, EVP Dave Fredrickson singled out the dual CD19/BCMA CAR-T candidate AZD0120 and the PD-1/TIGIT bispecific rilvegostomig as underappreciated growth drivers alongside the company’s ADC platform. On U.S. policy, Sarin outlined a phased Most Favored Nation agreement starting with Medicaid, expected to impact low single digits of global sales in 2026. The guidance for the coming year will incorporate this framework, while multiple Phase 3 readouts across therapy areas—ranging from datopotamab deruxtecan in lung cancer to rare-disease readouts for Ultomiris and asfotase alfa—are poised to serve as catalysts throughout 2026.